Patients Why Britain's blood tests are only as reliable as the journe... What happens in phlebotomy has a huge impact in pathology, and the different funding streams and management means that interests are no longer aligned
R&D From in silico to in vivo: Why development strategy now dete... As discovery becomes faster and more accessible, the differentiator shifts downstream.
Sales & Marketing Breaking tradition to reimagine medical affairs workflows fo... To stay relevant, medical affairs teams must adapt how they work to meet new demands with greater agility and efficiency.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.